Abstract The objective of the present study was to review previous investigations on the association of haplotypes in the G-protein b3 subunit (GNB3) gene with representative cardiovascular risk factors/phenotypes: hypertension, overweight, and variation in the systolic and diastolic blood pressures (SBP and DBP, respectively) and as well as body mass index (BMI). A comprehensive literature search was undertaken in Pubmed, Web of Science, EMBASE, Biological Abstracts, LILACS and Google Scholar to identify potentially relevant articles published up to April 2011. Six genetic association studies encompassing 16,068 participants were identified. Individual participant data were obtained for all studies. The three most investigated GNB3 polymorphisms (G-350A, C825T and C1429T) were considered. Expectation-maximization and generalized linear models were employed to estimate haplotypic effects from data with uncertain phase while adjusting for covariates. Study-specific results were combined through a random-effects multivariate meta-analysis. After carefully adjustments for relevant confounding factors, our analysis failed to support a role for GNB3 haplotypes in any of the investigated phenotypes. Sensitivity analyses excluding studies violating Hardy-Weinberg expectations, considering gender-specific effects or more extreme phenotypes (e.g. obesity only) as well as a fixedeffects ''pooled'' analysis also did not disclose a significant influence of GNB3 haplotypes on cardiovascular phenotypes. We conclude that the previous cumulative evidence does not support the proposal that haplotypes formed by common GNB3 polymorphisms might contribute either to Electronic supplementary material The online version of this article
Introduction
The guanine nucleotide-binding protein subunit b3 constitutes a major component of the heterodimeric G-proteins, which in turn act as signaling switches by integrating extracellular signals from ligand-activated G-protein-coupled receptors to downstream effectors [1] . Polymorphisms in the GNB3 (chromosome 12p) have been associated with essential hypertension (EH) and obesity [2, 3] , but there is evidence for statistical heterogeneity (i.e. variation in effect estimates beyond chance) [2] . Thus, a major question so far has been whether these polymorphisms display a genuine effect when considered individually, or whether they might modulate the risk of hypertension/obesity when only certain variants are co-inherited (e.g. cis-trans effects, in which the genetic effect would be only observed when markers are considered collectively). Indeed, the ubiquitous role of multi-marker effects [4, 5] and the importance of contrasting candidate polymorphisms against the background of other gene variants have been documented in the literature recently [4] [5] [6] [7] . In this respect, some investigators claim that haplotypes might exhibit a more prominent role in complex diseases such as hypertension and obesity [8] [9] [10] . The logic behind this statement stems from the fact that single-marker based analyses may be less powerful because a large amount of information contained in flanking regions of a genotyped marker is ignored. As a result, a more robust strategy would be a meta-analysis of haplotypes, which captures not only genetic information from different markers [6] but also data across independent studies [11] . Following these rationale, we conducted a review of previous studies on the association of haplotypes in the GNB3 gene with representative cardiovascular risk factors: hypertension, overweight, and variation in the systolic and diastolic blood pressures (SBP and DBP, respectively) and as well as BMI. Contrary to most metaanalyses, individual participant data were obtained for all studies, allowing us to present the results of individual studies adjusted for the same confounding factors. In addition, these data were used in a carefully conducted random-effects multivariate meta-analysis in an attempt to increase statistical power.
Materials and methods

Eligibility criteria
Studies (i) investigating the association of two or more GNB3 polymorphism either with blood pressure relatedphenotypes (e.g. EH, SBP and DBP), (ii) or with adiposityrelated traits (e.g. obesity, overweight, and BMI as a continuous trait), (iii) involving unrelated subjects and (iv) using validated methods of genotyping were considered eligible for the present meta-analysis.
Searches for potential studies were carried out using keywords described in detail elsewhere [2] as well as personal contact with experts in the field. The following databases (from inception through 01 April, 2011) were screened: Pubmed, Web of Science, EMBASE, Biological Abstracts, LILACS and Google Scholar. No restriction was imposed on (i) language of publication, (ii) ancestry of the examined population, (iii) original criteria used to define the presence of hypertension/obesity and (iv) publication status (published or unpublished).
Data collection and management
The corresponding author of each eligible study was contacted electronically with a project proposal and requests to provide individual-participant data. The following data were obtained from all studies: list of coding schemes and units, age, gender, SBP, DBP, BMI (in kg/m 2 ), use of antihypertensive medications, and genetic data for the investigated polymorphisms. Whenever available, data on lipids, presence of diabetes, and other important covariates were also obtained and included in sensitivity analyses. Data cleaning and standardization were performed in a single center to avoid potential center-specific biases. All studies were approved by the local ethical committees following the procedures of each country. Table 1 presents the three GNB3 polymorphisms investigated. These markers were chosen on the basis on their relative importance in expression assays as well as the available cumulative evidence (e.g. these markers are the most investigated GNB3 polymorphisms). Genotypes were scored by different genotyping technologies, but the accuracy of each method has been tested by a number of quality control measures in the original studies. These measures included re-genotyping of random samples by separate methods and Hardy-Weinberg testing. Detailed information on primers, probes, and other conditions for genotyping are available upon request.
Genetic markers
Phenotypes/outcomes
Phenotypes/outcomes of main interest were (i) EH classified according to the World Health Organization (WHO) criteria (SBP C 140 and/or DBP C 90 and/or use of anti-hypertensive drugs, in the absence of secondary forms of hypertension), (ii) overweight plus obesity defined as body mass index (BMI) C25 kg/m 2 and (iii) continuous traits, including both SBP and DBP and BMI. Secondary outcomes were (i) EH defined as SBP C 160 and/or DBP C 100 and/or use of antihypertensive drugs and (ii) obesity only, defined as a BMI C 30 kg/m 2 . Throughout the analyses, normotensive controls subjects were defined as those participants with a SBP \ 140 and DBP \ 90 and no history of use of antihypertensive drugs, whereas lean controls subjects were defined as those participants with a BMI \ 25 kg/m 2 . In order to avoid shrinkage in estimated effects for continuous variables, blood pressure levels in participants taking antihypertensive drugs were adjusted by adding 15 and 10 mm Hg for SBP and DBP, respectively, as described previously [12] .
Statistical analysis
Univariate meta-analysis
We estimated summary effects of individual GNB3 polymorphisms on cardiovascular phenotypes using the DerSimonian-Laird method, which is a method-of-momentsbased random-effects model [13] . We fit both additive and recessive models for markers with a minor allele frequency (MAF) below 30 %, and only an additive model for markers with a MAF C 30 %. Whenever two models of analysis were fit, results were correct by the Bonferroni method. This approach maximizes statistical power for variants that are less common in the populations, while reducing the likelihood of a type-I error (i.e. false-positive associations) in the analyses involving common markers [14, 15] .
The effect of individual variants on binary outcomes was captured as the natural logarithm of the odds ratio (OR) by means of multiple logistic regression models adjusted for age, gender and BMI when appropriate. For continuous traits, we fit a multiple linear regression model also adjusted for covariates. The effect size for continuous traits has the same units as the original variables and is captured as the expected linear increment (D) in the trait per additional copy of the risk-allele.
Haplotype estimation
For n biallelic markers, there are 2 n possible haplotypes, yielding 2 n -1 estimated haplotypic effects, which are obtained by comparing individual haplotypes with a reference haplotype, that is, the ''each haplotype versus the reference haplotype'' approach. For the ith study, a generalized linear model was employed to infer haplotypes, whereas simultaneously estimating haplotype frequencies and a vector haplotype effects [16] . The flexible generalized linear model applied here accounts for the uncertainty in haplotype assignment and permits the adjustment for covariates. Parameter estimates were obtained by the use of the expectation maximization (EM) algorithm, in which the extra uncertainty due to the unknown phase is taken into account, resulting in wider standard errors [16] . The variance-covariance matrix of regression parameters for each individual study was obtained as discussed previously [17] . For the present analyses, the haplotype containing only non-risk alleles was defined as the reference haplotype [6] . The regression schemes were consistently coined across studies to take into account a potential heterogeneity in the haplotypic frequencies. Inferences on the fit of alternative models (i.e. presence of statistically significant haplotypic effects) were carried out by using likelihood-ratio tests in a two-stage procedure as described elsewhere [4] .
Multivariate meta-analysis
In our case, multivariate meta-analysis explicitly models the relationship between correlated haplotypic effects within studies, ultimately producing more appropriate confidence intervals and P values [6] . Briefly, the method uses haplotypic effects (i.e. log of OR or D) obtained from the comparison of each of the 2 n -1 haplotypes against a reference haplotype and then models simultaneously the 2 n -1 haplotypic effects in a standard multivariate metaanalysis, taking into account the within-studies correlations that arise since the same reference group is included in each comparison. To fit the multivariate model, one requires not only the within-study variance for each effect, but also an estimate of the within-study covariance among haplotypic effects [18] .
We fit a random-effects multivariate meta-analysis, in which the jth possible haplotypic effect (j = 1,…,J = 2 n -1) estimated in the study i (Y ij ) for i = 1,…,k has a within-study sample variance assumed to be known of r . . .
where b is the J 9 1 vector of population specific haplotypic effects, X is the J 9 J within-study variancecovariance matrix, q ws is the within-study correlation between effects and MVN stands for the multivariate Normal distribution. Population specific effects (b ij ) with correspondent between-study variance (s 2 j ) are further assumed to be distributed as:
where l is the J 9 1 vector of average population specific haplotypic effects, P is the J 9 J between-study variancecovariance matrix and q bs is the between-study correlation between effects. Both l and P were estimated according the methodology described in detail elsewhere [19] . Hypothesis testing was carried out by multivariate Wald tests.
Statistical heterogeneity among haplotypic effects was assessed by the Cochran's Q-statistic [19, 20] , and the I 2 metric, which is the proportion of total variance of the pooled effect measure because of genuine statistical heterogeneity (i.e. due to between-study variance, and not to chance) [21] . Given the relatively large number of phenotypes and sub-groups studied (i.e. multiple testing), we considered a P \ 0.01 as a significant evidence for departures from HWE proportions. Similarly, for both haplotype-and meta-analysis-based inferences, a P \ 0.01 was judged significant. For the Q-statistic, a test with relatively low power in most scenarios [20] , a significance level of P \ 0.1 was chosen. Statistical analyses were carried out in Stata 11.1 package (Stata Corporation, College Station, TX, USA) and R (version 2.81).
Sensitivity analyses
Besides the main analyses, we also carried out multivariate meta-analyses of haplotypic effects (i) testing for nonadditive effects (i.e. both dominant and recessive models of action), (ii) excluding studies with markers not in HardyWeinberg Equilibrium, (iii) testing for gender-specific effects and (iv) considering only subjects without antihypertensive treatment. In addition, two other outcomes were investigated: a more severe stage of hypertension (defined as a SBP C 160 and/or DBP C 100 and/or use of antihypertensive) and obesity classified according to a BMI C 30 kg/m 2 . We further performed a fixed-effects pooled analyses encompassing each set of available studies, but added an additional term on the model referring the to study specific effects. We performed analyses in nondiabetic subjects only, Japanese participants only and repeated the main analysis adjusting for all available studyspecific covariates (e.g. total cholesterol, glucose, physical activity) when available. Finally, we applied an univariate random-effects meta-analysis for each outcome under an assumption of varying effect sizes between studies [22] .
Results
Characteristics of the participant studies
A total of six studies [23] [24] [25] [26] [27] [28] [29] were found. Of these, one [29] did not met our eligibility criteria (i.e. twin study). The selected characteristics of the six participating studies are shown in Table 2 . All studies were published between 2005 and 2011.
Single-marker-based meta-analysis
The G-350A promoter variant Four investigations encompassing 7,292 participants (2,738 hypertensives and 4,554 normotensives; 3,550 overweight and 3,742 lean) were available for the association of the G-350A promoter variant with both blood pressure-and adiposity-related phenotypes [23, 26, 28, 30] . All controls groups were in Hardy-Weinberg equilibrium (Supplementary Tables S1-S2 ). Overall, there was moderate to high degree of heterogeneity among study results, with the odds of essential hypertension, odds of overweight and DBP yielding nominally statistically significant evidence for statistical heterogeneity. Under an additive model, no evidence for an effect of the -350A allele on any of the investigated phenotypes was observed ( Table 3 ).
The C825T polymorphism in exon 10
All selected studies contributed with genotypic information in relation to the C825T polymorphism, yielding a total of up 15,960 participants with available data: 8,586 hypertensives and 7,372 normotensives; 6,133 overweight and 9,827 lean. The study by Suwazono et al. [30] . showed evidence for a departure from the Hardy-Weinberg proportions (exact P value = 0.003 and 0.008 for controls in EH and overweight, respectively (Supplementary Tables  S3-S4 ). Statistical heterogeneity was observed for DBP, BMI and odds of overweight. Random-effects summary estimates computed under an additive model suggested that the 825T allele has no influence on any of the investigated traits (Table 3) .
The C1429T variant at the 3 0 -untranslated region
For the C1429T variant, data from up to 12259 participants from four studies (6,642 hypertensives and 5,633 normotensives; 3,581 overweight and 8,678 lean) were available [23, 27, 30, 31] . For the odds of hypertension, controls subjects from the study by Suwazono et al. [30] . and Yamada et al. [31] . did not fit Hardy-Weinberg expectations (exact P values ranging from 0.005 to 0.001) (Supplementary Tables S5-S6 ). Confidence intervals for random-effects-based summary estimates overlap with null effects for all of the investigated phenotypes, indicating no prominent role of the 1429T allele in these traits (Table 3) .
Haplotype-based meta-analysis
G-350A-C825T haplotypes
Four studies had participants genotyped for both G-350A and C825T variants, enabling haplotypic analyses that encompassed 7,292 participants (2,738 hypertensives and DBP diastolic blood pressure, SBP systolic blood pressure, OR odds ratio, D expected linear increment in the trait per additional copy of the riskallele, s 2 estimated between-study variance, P(Q) P value for the Cochran's Q test 4,554 normotensives; 3,550 overweight and 3,742 lean) [23, 26, 28, 30] . While a distinct pattern of LD among populations of different ancestries is observed, we found evidence for a significant LD and high to moderate D 0 scores between the G-350A variant and the C825T polymorphism (P \ 0.01 for all studies, Supplementary Table  S7 ). Among Japanese, the two common haplotypes GC and GT captured [98 % of the chromosomes, but only 60-70 % in other ancestries. Under a multivariate random-effects meta-analysis with additive effects, none of the three haplotypes containing risk alleles (i.e. GT, CA, and AT) showed significant evidence of association with the investigated traits compared to the reference GC haplotype. Overall, evidence for heterogeneity was only observed for the odds of hypertension. For this trait, heterogeneity was observed in both magnitude and direction of the effects (Table 4) .
C825T-C1429T haplotypes
Data from 12,259 participants from four studies [23, 27, 30, 31] were available to test the association of the C825T-C1249T haplotypes with cardiovascular phenotypes (6,644 hypertensives and 5,615 normotensives; 3,581 overweight and 8,678 lean). All participants were of Asian descent. Both D 0 and R 2 measures suggested significant LD, which was observed to be consistent among studies (Supplementary Table S9 ).
When studies were combined through a random-effects multivariate meta-analysis, none of the inferred haplotypes displayed a significant effect on the investigated traits compared to the reference CC haplotype (Table 5) .
G-350A-C1429T haplotypes
Both G-350A and C1429T variants were genotyped in two studies [23, 30] , yielding an analysis that incorporated data from 3649 subjects of Asian ancestry (813 hypertensives and 2,836 normotensives; 1,026 overweight and 2,623 lean). Given that the -350A and 1429T alleles are typically uncommon in Asian populations, a single common haplotype (i.e. the basal GC haplotype) captured C75 % of the chromosomes and there was evidence for linkage disequilibrium (Supplementary Table S10 ). Under a randomeffects meta-analysis, none of the inferred G-350A-C1429T haplotypes showed significant effects on the studied phenotypes compared to the GC reference haplotype (Table 6 ).
G-350A-C825T-C1429T haplotypes
Inferences on the effect of the G-350A-C825T-C1429T haplotypes on blood pressure and adiposity-related traits was possible in the same set of subjects from the previous analysis (3,649 participants of Asian descent) [23, 30] . Among the eight possible haplotypes, three were most common, capturing [97 % of the chromosomes. Due to convergence problems originated from haplotypes with very low frequency, we pooled uncommon haplotypes into a single category (Supplementary Table S11 ). Under a random-effects multivariate meta-analysis, no significant association was detected between the two most common haplotypes (i.e. GTC and GTT) and the pooled category (all haplotypes with a frequency below 3 %) with any of the studied phenotypes (Table 7) .
Sensitivity analyses
No significant effects were observed in any of these sensitivity analyses (data not shown).
Discussion
Main findings
The present study is a comprehensive, carefully conducted international collaborative meta-analysis of individual patient data that reviewed the role of GNB3 haplotypes in five traits of cardiovascular importance. By using participant-level data from 16068 subjects, our results do not support the hypothesis of significant effects of GNB3 polymorphism/haplotypes neither on the risk of essential hypertension and overweight nor on continuous traits such as SBP, DBP and BMI.
Agreements and disagreements with other studies or systematic reviews
Considering the evidence as a whole, our findings are in line with recent meta-analyses on the association of individual GNB3 markers and hypertension that used summary data [32, 33] . Recent large-scale association studies also suggest no evidence for an association between GNB3 polymorphisms either with systolic and diastolic blood pressures as continuous variables or essential hypertension as a dichotomous phenotype [34] . Dong et al. [29] were the first to present evidence for GNB3 haplotypic effects on cardiovascular-related phenotypes in a sample of female dizygotic twins. According to the authors, there was evidence for a complex interaction among GNB3 haplotypes versus obesity versus hypertension. Among the six studies included in the present systematic review, only two [23, 28] explicitly investigated and claimed a role for GNB3 haplotypes in cardiovascularrelated phenotypes. For example, Li et al. [23] revealed the potential of haplotypic effects when assessing the influence of GNB3 polymorphisms on the risk of hypertension in Chinese. Recently, by using a family-based design and dimensionality reduction techniques, Kimura et al. [28] were able to observe that both G-350A and C825T variants might interact to determine DBP levels in an Africanderived Brazilian population. It is important to note that, in all of the three studies mentioned above, significant results were obtained after multiple testing, and were only marginally significant with P values ranging from 0.01 to 0.04.
Study strengths and limitations
A relatively large number of participants with individual data might be considered a strong point in our work. Indeed, a key aspect of our investigation is that our results are less prone to reporting bias, since all data from each individual study were used in our analyses. All results were summarized after adjustment for the same covariates and are presented in a uniform manner. Criticism might be directed at the fact that we meta-analyzed data from samples with substantial differences in genetic background (three Japanese, one Chinese, one European and one Brazilian with African ancestry). However, we consider the use of multiethnic samples a further strength in our work.
In fact, it is well-known that single populations can only capture a limited proportion of the total human genetic variation. By analyzing data from diverse populations, we were unable to detect strong support for the association of GNB3 haplotypes either at an individual study or at a metaanalysis level. Although these findings do not rule out small, population-specific effects, we might consider less likely large effects of GNB3 haplotypes on cardiovascular phenotypes in the studied populations. Importantly, we noted several limitations that should be considered in interpreting our findings. Firstly, although we have included age, gender and BMI in association analyses involving blood pressure-related phenotypes, several other covariates such as lipids and salt consumption were not included due to the lack of information in some studies. This statement is also valid for the risk of overweight and BMI as a continuous variable, in which physical activity was not available for all investigations.
Moreover, some limitations of haplotypic-based metaanalysis are worth of consideration. For example, our metaanalysis is based on previous published literature. Although we enrolled six independent studies in the meta-analysis, the number of genotyped SNPs was different across studies. As a result, sample sizes were considerably different among haplotypic analyses. Secondly, it is believed that haplotypebased meta-analyses may render higher statistical power to disclose associations of moderate to small effects [11, 29, 35] . This notion has been strongly empathized recently [36] . However, we noted several caveats when conducting a metaanalysis of haplotype effects. The fist caveat is illustrated by the difficulty to model effects from uncommon haplotypes. For example, when some of the investigated variants are less frequent in the populations, GLM models such as the one used here may originate estimates with large uncertainty (i.e. very large confidence intervals). Consequently, the apparent advantage of meta-analyses of haplotype-effects may be concealed. This occurs because even considerably high effects from uncommon haplotypes may yield meta-analyses with markedly reduced statistical power due to larger uncertainty around point estimates. Furthermore, the construction of useful models is likely to require the specification of a threshold frequency below which uncommon haplotypes are pooled into a single category [17] . In other words, combination of several haplotypes into a single group jeopardizes the interpretation and generalizability of results. In this regard, future meta-analyses of haplotypic effects will benefit of the development and use of new approaches for the estimation of effects from rare haplotypes [37] . In addition, haplotype-based analyses assume that HardyWeinberg Equilibrium holds for the whole population. Hence, the violation of theses expectations in some studies may augment or diminish the accuracy of the estimated haplotype frequencies [38] , resulting in bias in haplotypic effects. Finally, funnel plot and formal statistical approaches were not employed to identify small-study biases because the number of available studies was \10 [39] .
Conclusion
Allowing for the methodological caveats, the cumulative evidence does not support the proposal that the haplotypes formed by common polymorphisms in the GNB3 might exert influence on representative cardiovascular factors/phenotypes such as hypertension, overweight, SBP, DBP and BMI. Our results do not rule out potential GNB3 haplotypic effects either on pharmacogenetic traits or preeclampsia.
